



VIRGINIA DRUG DISCOVERY CONSORTIUM
VIRGINIA BRAIN RX:

A SYMPOSIUM ON DRUG DISCOVERY FOR THE BRAIN

MAY 23 - 24, 2016
OMNI RICHMOND HOTEL
RICHMOND, VIRGINIA

Revision date 4/12/16.

Day 1 (Monday May 23, 2016) Chairs: David G. I. Kingston, Richard A. Glennon

11:00 am Registration opens

1:00 pm Symposium Opens:

Welcome from David G. I. Kingston, Ph.D. (VT), Meeting Chair

Welcome from VBHRC/The Catalyst: Mike Grisham (Virginia Biosciences Health Research Corporation).

Welcome from Delegate John O'Bannon, M.D. (73rd District, Virginia)

1:15 pm "Origins, Status, and Future of the Virginia's Neuroscience Initiative, aka The Brain State"

Mike Friedlander, Ph.D. (Virginia Tech, Carilion Research Institute)

George Bloom, Ph.D. (Biology and Cell Biology, University of Virginia)

1:30 pm **Keynote 1** "Developing Therapeutics for Substance Use Disorders: Progress and Outlook": [Phil Skolnick, Ph.D., D.Sc. \(hon.\)](#) (Director, DTMC, NIDA, NIH)

2:05 pm Q & A

2:15 pm **Keynote 2** "Opportunities in CNS Drug Development: an Industry Perspective"
[Darryle Schoepp, Ph. D.](#) (V.P. and Therapeutic Area Head, Neuroscience, Merck)

2:55 pm Q & A

3:00 pm Coffee break/Poster Session

3:30 pm **Keynote 3** "Lessons Learned in Building an Academic Drug Discovery Center":
[Craig Lindsley, Ph. D.](#) (Co-director, Vanderbilt Center for Neuroscience Drug Discovery).

- 4:10 pm Q & A
- 4:15 pm Opportunities for inter-institutional collaboration within the Commonwealth. Resource Inventories at EVMS, ODU, GMU, UVA, VCU, VT: VPRs (or their designees)
- 5:15 pm Day 1 Wrap-up: Richard Glennon, Ph.D. (VCU)
- 5:30 pm Social Hour & Networking/Poster Session
- 6:30 pm Dinner

Day 2 (Tuesday, May 24, 2016) Chairs: John S. Lazo, Paul R. Carlier

- 8:00 am Breakfast
- 9:00 am Welcome to Day 2: John S. Lazo, Ph.D. (UVA)
- Keynote 4** “Parkinson’s Disease: Meeting the Challenge” [Todd Sherer, Ph. D.](#) (CEO, Michael J. Fox Foundation).
- 9:45 am Introduction to Commonwealth of Virginia speakers.
- 9:50 am “Amyloid & Tau: The Trigger and Bullet in Alzheimer’s Disease Pathogenesis” [George Bloom, Ph. D.](#) (Professor of Biology & Cell Biology, University of Virginia).
- 10:05 am “The Medicines for All Initiative” [B. Frank Gupton, Ph.D.](#) (Chair, Chemical & Life Science Engineering, Virginia Commonwealth University).
- 10:20 am “New use for an old drug: Sulfasalazine to treat tumor associated epilepsy” [Harald Sontheimer, Ph. D.](#) (Director, Neuroscience Program, Virginia Tech).
- 10:35 am Coffee Break/Poster Session
- 11:10 am “Insights from an Integrated Approach to Animal Behavioral Models” [Larry D. Sanford, Ph.D.](#) (Professor of Pathology and Anatomy, Eastern Virginia Medical School)
- 11:25 am “Preclinical and Clinical Applications of Drug and Gene Electrotransfer” [Richard Heller, Ph.D.](#) (Professor, Frank Reidy Center for Bioelectrics, Old Dominion University)
- 11:40 am “The role of the nicotinic acetylcholine receptor in axon growth and regeneration” [Nadine Kabbani, Ph.D.](#) (Associate Professor, Molecular Neuroscience and Krasnow Institute for Advanced Study, George Mason University)
- 11:55 am Closing Remarks for the Morning Session.

- 12:00 pm Lunch and networking/Poster Session
- 1:00 pm **Keynote 5** “Challenges and Opportunities in Psychiatric Drug Development”
[Thomas Laughren, M.D.](#) (Director, Regulatory Affairs, MGH Clinical Trials Network and Institute).
- 1:45 pm **Panel Discussion:** What are Industry’s “Conditions for Satisfaction” in Drug Discovery Collaborations with Academia?
- Mike Grisham (VBHRC), Moderator
Rita Balice-Gordon, Ph.D. (Pfizer), Ryan Westphal, Ph.D. (Lilly), Michael Wood, Ph.D. (AstraZeneca), Frank D. Yocca (BioXcel).
- 2:55 pm Closing Remarks: Paul R. Carlier, Ph.D. (VT).

